Lannett Announces Closing of Registered Public Offering of Common Stock
2010年12月18日 - 3:42AM
ビジネスワイヤ(英語)
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic
pharmaceuticals, today announced the closing of its previously
announced underwritten registered public offering of 5,000,000
shares of its common stock. The company offered 2,500,000 shares of
common stock and a selling stockholder of the company offered
2,500,000 shares of common stock. The net proceeds to Lannett from
the sale of the shares, after the underwriting discounts and
commissions and estimated offering expenses payable by Lannett, are
expected to be approximately $11.4 million.
The company said it intends to use the net proceeds of the
offering for general corporate purposes, including, without
limitation, research and development expenses, general and
administrative expenses, expansion of its API manufacturing
operations at Cody Labs and its dosage operations at Lannett,
manufacturing expenses, potential acquisitions of companies,
technologies and properties, complementary to Lannett’s business
(although the company is not currently party to any binding
agreements or commitments with respect to any such acquisitions)
and working capital. Pending these uses, the company expects to
invest the net proceeds in investment-grade, interest-bearing
instruments.
Oppenheimer & Co. and Roth Capital Partners acted as co-book
running managers, and Emerging Growth Equities acted as co-manager
for the offering. The company has also granted the underwriters a
30-day option to purchase up to 750,000 shares to cover
over-allotments, if any.
The securities described above are being offered by Lannett and
the selling stockholder pursuant to a “shelf” registration
statement on Form S-3, Registration Number 333-162318, previously
filed with the Securities and Exchange Commission (SEC) and
declared effective by the SEC on November 20, 2009. A prospectus
supplement related to the offering dated December 14, 2010 and
filed with the SEC on December 15, 2010 is available on the SEC’s
web site at http://www.sec.gov. The prospectus supplement and
accompanying base prospectus may be obtained by sending a request
to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus
Department, 300 Madison Avenue, 5th Floor, New York, NY, 10017,
Telephone number: (212) 667-8563, Email: EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures,
packages, markets and distributes generic pharmaceutical products
for a wide range of indications. For more information, visit
Lannett Company’s website at www.lannett.com.
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Any such statements, including, but not limited to,
Lannett’s expectations regarding the completion, timing and size of
its public offering, whether expressed or implied, are subject to
risks and uncertainties which can cause actual results to differ
materially from those currently anticipated due to a number of
factors which include, but are not limited to, risks and
uncertainties associated with market conditions, and other risk
factors discussed in the company’s Form 10-K and other documents
filed with the Securities and Exchange Commission from time to
time. These forward-looking statements represent the company's
judgment as of the date of this news release. The company disclaims
any intent or obligation to update these forward-looking
statements.
London Clubs (AMEX:LCI)
過去 株価チャート
から 6 2024 まで 7 2024
London Clubs (AMEX:LCI)
過去 株価チャート
から 7 2023 まで 7 2024